Iktos secured €15.5 million in Series A funding to enhance its AI-driven drug discovery platform and launch an automated service, positioning itself as a pioneer in the pharmaceutical sector.
Target Information
Iktos is a pioneering company specializing in the application of artificial intelligence (AI) to drug discovery. Recently, Iktos secured €15.5 million in Series A financing, co-led by new investors M Ventures and the Debiopharm Innovation Fund, alongside participation from Omnes Capital. This funding aims to enhance Iktos' AI technology platform and facilitate the launch of Iktos Robotics—an advanced, AI-driven automated drug discovery service.
The capital raised will allow Iktos to further enhance its AI capabilities and drug discovery offerings. Additionally, Iktos plans to introduce Iktos Robotics, a unique platform that integrates AI and automation for chemical synthesis, thus accelerating the drug development timeline. The company also intends to extend its solutions to biological products, such as peptides and antibodies, positioning itself as one of the first providers of fully integrated drug discovery services within the pharmaceutical sector.
Access Full Deal Insights
You’re viewing a public preview of this deal. To unlock full access to ca. 50,000 other deals in our database and join ca. 400 M&A professionals who are using it daily, sign up for Dealert.
Industry Overview in the Target's Country
The pharmaceutical industry in France is one of the largest in Europe, characterized by a robust framework of regulatory standards, research institutions, and strong public-private partnerships. France has cultivated a highly skilled workforce in biopharmaceutical s
Similar Deals
China Development Industrial Bank → Anbogen Therapeutics
2024
M Ventures, Debiopharm Innovation Fund
invested in
Iktos
in 2023
in a Series A deal
Disclosed details
Transaction Size: $16M